Effect of specific immunotherapy on serum interleukin-4, interleukin-18 and transforming growth factor-betal for the treatment of bronchial asthma in children / 中国医师进修杂志

ABSTRACT

Objective To observe the effect of specific immunotherapy on serum interleukin-4 (IL-4),interleukin-18 (IL-18) and transforming growth factor-beta 1 (TGF-β 1) for the treatment of bronchial asthma in children.Methods Seventy-five patients with bronchial asthma in children were divided into observation group(38 cases) and control group(37 cases) by random digits table method.The control group was received drug treatment,the observation group was given specific immunotherapy on the basis of the control group.After 12 months of treatment,the level of forced expiratory volume in 1 second (FEV1),FEV1/forced vital capacity (FVC),FVC,peak expiratory flow (PEF) such as lung function and serum IL-4,IL-18 and TGF-β1 between two groups was compared and the level of serum IL-4,IL-18 and TGF-β1 was compared among different efficacy.Results After 12 months of treatment,the level of FEV1,FEV/FVC,FVC,PEF was (2.82 ± 0.35) L,(81.65 ± 5.38)％,(3.46 ± 0.45) L,(5.61 ± 1.44) L/s in observation group,(2.17 ±0.29) L,(72.84 ±4.82)％,(3.24 ±0.41) L,(5.08 ± 1.35) L/s in control group,and there was significant difference (P ＜ 0.05).After 12 months of treatment,the level of serum IL-4,IL-18 and TGF-β1 was (5.94 ± 4.76) ng/L,(192.85 ± 54.06) ng/L,(6.17 ± 0.42) μ g/L in observation group,(7.26 ± 5.33) ng/L,(259.61 ± 67.83) ng/L,(6.83 ± 0.48) μ g/L in control group,and there was significant difference(P ＜ 0.05).There was significant difference in the level of serum IL-4,IL-18 and TGF-β1 among different efficacy(P ＜ 0.05).Conclusion IL-4,IL-18 and TGF-β 1 in children with bronchial asthma are involved in the inflammatory response,serum IL-4,IL-18 and TGF-β1 levels can provide the basis for the treatment and prognosis of bronchial asthma in children.